Browse studies, page 1088
Page 1088 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Patients With Coronary Heart Disease and Heart Failure Treated With Empagliflozin Clinical Therapeutics, 2025
- Empagliflozin role in the treatment of type 2 diabetes with cardiovascular disease and subclinical cardiovascular disease in outpatient setting: case reports Journal of Diabetes Metabolic Disorders & Control, 2020
- Combination Therapy with Empagliflozin and Insulin Results in Successful Glycemic Control: A Case Report of Uncontrolled Diabetes Caused by Autoimmune Pancreatitis and Subsequent Steroid Treatment Case Reports in Endocrinology, 2019
- Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review BMC Nephrology, 2020
- Sodium glucose co-transporter-2 inhibitors in intensive care unit patients with type 2 diabetes: a pilot case control study Critical Care, 2023
- Management and Diagnosis of Empagliflozin-Induced Burning Mouth Syndrome: A Case Report Cureus, 2024
- Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report International Journal of Diabetes in Developing Countries, 2022
- Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Frontiers in Endocrinology, 2022
- Effectiveness of Sitagliptin and Empagliflozin Combination Therapy in a Patient With Charcot-Marie-Tooth Disease and Comorbid Diabetes Mellitus: A Case Report Cureus, 2025
- Case Report: The long-term effects of the empagliflozin therapy on glycemia and renal function in a patient with Rabson-Mendenhall syndrome caused by two heterozygous variants in INSR gene Frontiers in Endocrinology, 2025
- The effects of SGLT2 inhibitors in patients with preserved ejection fraction heart failure and type 2 diabetes: A randomized case-control study European Heart Journal, 2025
- Empagliflozin and Arterial Stiffness in Patients with Type 2 Diabetes: A Real-World Case-Control Study Endocrine, Metabolic & Immune Disorders - Drug Targets, 2025
- Real-world impact of empagliflozin on total cost of care in adults with type 2 diabetes: Results from an outcomes-based agreement Journal of managed care & specialty pharmacy, 2023
- Clinical Spectrum and Mechanism of Acute Kidney Injury in Patients with Diabetes Mellitus on SGLT-2 Inhibitors The Israel Medical Association journal : IMAJ, 2018
- A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience The Journal of the Association of Physicians of India, 2021
- Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes Journal of diabetes research, 2022
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s Obesity (Silver Spring, Md.), 2016
- Case report: The success of empagliflozin therapy for glycogen storage disease type 1b Frontiers in endocrinology, 2024
- Empagliflozin Use in Cardiac Transplant Patients: Real-world experience from Saudi Arabia Sultan Qaboos University medical journal, 2025
- Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose Diabetes, 2017
- Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center Journal of cardiovascular pharmacology, 2020
- Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019
- Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events Diabetes care, 2020
- Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation Journal of pediatric endocrinology & metabolism : JPEM, 2023
- Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes The Journal of clinical endocrinology and metabolism, 2018
- Sodium-glucose co-transporter-2 inhibitors eligibility in patients with heart failure with reduced ejection fraction International journal of cardiology, 2021
- The safety of sodium glucose transporter 2 inhibitors and trends in clinical and hemodynamic parameters in patients with left ventricular assist devices Artificial organs, 2024
- Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus The journal of medical investigation : JMI, 2020
- Risk of Urinary Infections in Veterans on Empagliflozin With Concurrent Catheter Use Journal of pharmacy practice, 2024
- A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country International journal of clinical pharmacy, 2022
- New-onset Diabetes Mellitus After Adult Heart Transplantation and the Risk of Renal Dysfunction or Mortality Transplantation, 2022
- Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors Diabetes & metabolism journal, 2019
- Relationship between Presence of Visceral Infarction and Functional Outcome among Patients with Acute Ischemic Stroke Cerebrovascular diseases (Basel, Switzerland), 2020
- Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitor in Heart Transplant Recipients with Chronic Kidney Disease International heart journal, 2026
- Impact of Inpatient Initiation of SGLT2 Inhibitors on Diuretic Requirements in Patients With Heart Failure Journal of pharmacy practice, 2024
- Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease PloS one, 2022
- Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa Journal of the American Heart Association, 2026
- Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction? Kardiologia polska, 2021
- Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study Current medical research and opinion, 2020
- The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors Cardiovascular diabetology, 2020
- Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study ESC heart failure, 2025
- Comparative evaluation of clinical outcomes of dapagliflozin and empagliflozin in type-2 diabetes mellitus Irish journal of medical science, 2023
- Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), 2023
- SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Diabetes, obesity & metabolism, 2018
- Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data Diabetes, obesity & metabolism, 2024
- Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire Genetics in medicine : official journal of the American College of Medical Genetics, 2022
- Use of Sodium-glucose Cotransporter 2 Inhibitors in Patients with Chronic Kidney Disease Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2023
- Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit Journal of pharmacy practice, 2024
- Exploratory Mediation-Informed Analysis and Dose-Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol Medical sciences (Basel, Switzerland), 2026
- Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System Journal of general internal medicine, 2022
- Rates of diabetic ketoacidosis with empagliflozin use during hospitalization for acute heart failure Journal of hospital medicine, 2024
- Liver Fibrosis Indices and Outcomes After Primary Intracerebral Hemorrhage Stroke, 2020
- Evaluation of the effect of sodium-glucose cotransporter-2 inhibitor treatment on choroidal vascular parameters in patients with type 2 diabetes mellitus Photodiagnosis and photodynamic therapy, 2023
- Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2023
- Efficacy and safety of empagliflozin: a "real-world" experience from Saudi Arabia Annals of Saudi medicine, 2023
- Progress of patients hospitalized with acute heart failure treated with empagliflozin Journal of comparative effectiveness research, 2024
- Outpatient medications associated with protection from COVID-19 hospitalization PloS one, 2023
- Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus American journal of physiology. Renal physiology, 2015
- Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs The Journal of the Association of Physicians of India, 2018
- Adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes-A systematic review Pharmacology research & perspectives, 2024
- Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features Cardiovascular diabetology, 2025
- Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria American Society of Nephrology. Clinical Journal, 2024
- Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction PLoS ONE, 2024
- Dapagliflozin versus empagliflozin in patients with heart failure with preserved ejection fraction European Heart Journal, 2025
- Empagliflozin versus dapagliflozin in heart failure European Heart Journal, 2025
- 1193-P: Health-Care Costs and Medication Burden in Routine Care Initiators of Empagliflozin: A First Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study Diabetes, 2019
- P5003Reduced healthcare utilization in routine care initiators of empagliflozin with and without heart failure: interim analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study European Heart Journal, 2019
- Empagliflozin vs. dapagliflozin in heart failure: a target trial emulation Journal of Cardiac Failure, 2025
- The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia Journal of Family Medicine and Primary Care, 2025
- Growth differentiation factor 15: A biomarker to guide empagliflozin treatment in acute myocardial infarction? International Journal of Cardiology, 2025
- SGLT2i compared to other non-insulin antidiabetics in Primary Care patients with earlier diabetes. Cohort profile and sample characteristics of DIAB-CV-AP study Semergen, 2026
- Abstract 10855: Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patients: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study Circulation, 2021
- Abstract 12579: Empagliflozin and the Risk of Atherosclerotic Events and Hospitalization for Heart Failure: Updated Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study Circulation, 2021
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study British medical journal, 2018
- Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis Diabetes Therapy, 2021
- Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021
- Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study British medical journal, 2020
- Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study Diabetes Care, 2022
- Effect of sodium-glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims-based cohort study Journal of Diabetes Investigation, 2026
- 870-P: Empagliflozin and the Risk of Gout—Analysis from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study Diabetes, 2023
- 269-OR: Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes—Results from the EMPRISE Study Diabetes, 2023
- A Prospective Cohort Study on the Impact of SGLT2 Inhibitors on the 12‑Month Recurrence Risk of Atrial Fibrillation After Catheter Ablation Drug Design, Development and Therapy, 2026
- Clinical and Medication-Related Factors Associated with Adverse Renal Outcomes in Advanced Chronic Kidney Disease Patients Treated with Empagliflozin: A Real-World Study in Thailand Pharmacoepidemiology, 2026
- Empagliflozin in paediatric heart failure: model-based optimisation of a pharmacokinetic bridging study Frontiers in Medicine, 2026
- Individual SGLT-2 Inhibitors and Risk of New-Onset Cancer in Type 2 Diabetes: A Nationwide Population-Based Cohort Study Cancer research and treatment : official journal of Korean Cancer Association, 2026
- Real-world efficacy and safety of SGLT2 inhibitor add-on triple therapy in south indian patients with type 2 diabetes mellitus: a 24-week prospective observational cohort study Diabetology & Metabolic Syndrome, 2026
- Sex-Based Differences in Clinical Outcomes Among Heart Failure Patients Treated With SGLT2 Inhibitors: Insights From a Multicenter Cohort Study Global Cardiology Science & Practice, 2026
- SGLT2 inhibitors and outcomes in the chronic Post-LVAD phase: a multicenter real-world cohort study Frontiers in Pharmacology, 2026
- Wound healing outcomes in diabetic kidney disease patients receiving SGLT2 inhibitor therapy: a prospective propensity score-matched cohort study Frontiers in Endocrinology, 2026
- Patient and prescriber knowledge of SGLT2i sick day rules: a single centre cohort study European Journal of Heart Failure, 2026
- Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA BMJ mental health, 2026
- Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study PharmacoEconomics - Open, 2023
- Risk of prostatitis in patients with type 2 diabetes mellitus: An observational retrospective cohort study of canagliflozin versus other antihyperglycemic agents using propensity score matching PLoS ONE, 2026
- Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study Diabetes & Metabolism, 2023
- Impact of Sodium-Glucose Co-Transporter Type-2 Inhibitors on Alanine Aminotransferase Levels in Type-2 Diabetes Patients Having Features of Nonalcoholic Fatty Liver Disease: A Retrospective Cohort Study in Pakistan Pakistan Journal of Medical Sciences, 2024
- Impact of Empagliflozin on the Outcomes of β-Thalassemia Major in Patients With Type 2 Diabetes Mellitus: The THALEMPA Observational Study Cureus, 2024
- Impact of Sglt-2 Inhibitors on Sickle Cell Disease Patients with Type 2 Diabetes: A Retrospective Matched Cohort Study Blood, 2024
- 1340-P: The Association of SGLT2i vs. DPP4i on Fracture—Cohort Study of Veterans with Diabetes Diabetes, 2024
- The Impact of Empagliflozin on Inflammatory Markers in Adults with Type 2 Diabetes: A Retrospective Cohort Medical Journal of The Islamic Republic of Iran, 2024
- Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study Frontiers in Pharmacology, 2024
